Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical Hainan Co Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Qilu Pharmaceutical (Hainan) Co., Ltd. (China)
  • Plaintiff’s Counsel: Saul Ewing LLP; Quinn Emanuel Urquhart & Sullivan, LLP
• Case Identification: 1:26-cv-01633, D.N.J., 02/18/2026
• Venue Allegations: Venue is alleged to be proper as Defendant conducts business in the United States, including the District of New Jersey, and the district is a likely destination for the accused generic drug product.
• Core Dispute: Plaintiff alleges that Defendant’s filing of an Abbreviated New Drug Application (ANDA) for a generic version of the antiviral drug LIVTENCITY® (maribavir) constitutes an act of infringement of six U.S. patents related to maribavir compositions, synthesis methods, and treatment regimens.
• Technical Context: The technology concerns maribavir, an orally available antiviral medication indicated for treating post-transplant cytomegalovirus (CMV) infection, a significant complication for transplant recipients.
• Key Procedural History: The lawsuit was triggered by Defendant’s submission of ANDA No. 221142 to the U.S. Food and Drug Administration (FDA) and its subsequent Paragraph IV certification notice, signaling its intent to market a generic version of maribavir prior to the expiration of Plaintiff’s patents.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632 - "`Maribavir Isomers, Compositions, Methods of Making and Methods of Using`"

• Issued: June 27, 2023

The Invention Explained

• Problem Addressed: The patent discloses the "unexpected discovery that maribavir may isomerize under in vivo conditions" into different molecular forms (isomers) ’632 Patent, col. 2:55-57 This chemical conversion within the body is believed to dilute the concentration of the effective drug, which can decrease its biological activity and therapeutic efficacy, potentially explaining the failure of a prior Phase 3 clinical trial ’632 Patent, col. 2:5-18 ’632 Patent, col. 2:19-29
• The Patented Solution: The invention claims to enhance maribavir's therapeutic efficacy by proposing methods of administration that "prevent or at least reduce the unwanted occurrence of maribavir isomerization in vivo" ’632 Patent, col. 3:1-5 A key aspect of the solution involves administering the drug under "fasted conditions," which is intended to mitigate the adverse effects of isomerization and improve the drug's bioavailability ’632 Patent, col. 4:52-56 ’632 Patent, col. 5:1-3
• Technical Importance: The claimed methods provide a way to control an in-vivo chemical transformation of maribavir, thereby seeking to ensure consistent and effective therapeutic concentrations in patients.

Key Claims at a Glance

• The complaint does not specify which claims are asserted but states infringement of "one or more claims" Compl. ¶33 Independent claim 1 is representative:
• A method for treatment of a herpes viral infection in a patient in need thereof comprising:
  • orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound
  • in an amount of 400 mg twice a day
  • wherein said patient is a stem cell transplant recipient

U.S. Patent No. 12,213,989 - "`Use of Maribavir in Treatment Regimens`"

• Issued: February 4, 2025

The Invention Explained

• Problem Addressed: The patent background section notes that transplant recipients often receive numerous medications simultaneously, creating a risk of drug-drug interactions ’989 Patent, col. 1:24-28 Specifically, maribavir is metabolized by the enzyme CYP3A4, and co-administration with drugs that induce (i.e., increase the activity of) CYP3A4 can lead to decreased maribavir plasma concentrations and potentially reduced antiviral efficacy ’989 Patent, col. 1:36-47 ’989 Patent, col. 6:9-14
• The Patented Solution: The patent provides dosing regimens to counteract this interaction. The claimed solution involves administering an increased dose of maribavir to a patient who is also receiving a CYP3A4-inducing drug (such as the anticonvulsants phenytoin or phenobarbital) to maintain a therapeutically effective amount of maribavir ’989 Patent, summary ’989 Patent, col. 2:11-18
• Technical Importance: This invention provides a specific dosing strategy to maintain the efficacy of an antiviral drug in patients with complex medication schedules, a common clinical scenario in transplant recipients.

Key Claims at a Glance

• The complaint does not specify which claims are asserted but alleges infringement of "one or more claims" Compl. ¶42 Independent claim 1 is representative:
• A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising:
  • administering maribavir in an amount of 1200 mg orally twice-daily
  • wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital
  • wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant

U.S. Patent No. 12,295,940 - "`Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto`"

• Issued: May 13, 2025
• Technology Synopsis: This patent discloses methods for synthesizing maribavir and its intermediates ’940 Patent, abstract The invention relates to chemical processes that may result in compositions of maribavir with specific purity profiles, such as having low levels of certain byproducts or impurities ’940 Patent, col. 8:50-54
• Asserted Claims: The complaint does not specify asserted claims Compl. ¶51
• Accused Features: The complaint alleges that Defendant’s submission of its ANDA for the Qilu ANDA Product constitutes infringement, suggesting the product itself is either made by a claimed process or embodies a claimed composition Compl. ¶¶51-53

U.S. Patent No. 12,433,907 - "`Use of Maribavir in Treatment Regimens`"

• Issued: October 7, 2025
• Technology Synopsis: This patent, similar to the ’989 Patent, addresses drug-drug interactions involving maribavir ’907 Patent, background It provides methods for adjusting maribavir dosage when co-administered with drugs that induce the CYP3A4 enzyme, in order to maintain therapeutic effectiveness ’907 Patent, summary
• Asserted Claims: The complaint does not specify asserted claims Compl. ¶60
• Accused Features: The complaint alleges that the commercial manufacture, use, or sale of the Qilu ANDA Product will infringe, presumably by inducing administration according to the claimed dosing regimens Compl. ¶¶62-63

U.S. Patent No. 12,447,169 - "`Maribavir Isomers, Compositions, Methods of Making and Methods of Using`"

• Issued: October 21, 2025
• Technology Synopsis: This patent, similar to the ’632 Patent, relates to the in-vivo isomerization of maribavir and methods to mitigate its effects ’169 Patent, background The invention includes methods of administering maribavir, such as with or without food, to enhance bioavailability and therapeutic efficacy by reducing unwanted isomerization ’169 Patent, col. 4:50-56 ’169 Patent, col. 5:1-3
• Asserted Claims: The complaint does not specify asserted claims Compl. ¶69
• Accused Features: The infringement allegation targets the Qilu ANDA Product, suggesting its eventual use will follow the claimed methods of administration Compl. ¶¶71-72

U.S. Patent No. 12,447,170 - "`Use of Maribavir in Treatment Regimens`"

• Issued: October 21, 2025
• Technology Synopsis: This patent, similar to the ’989 and ’907 Patents, discloses methods for managing drug-drug interactions when administering maribavir ’170 Patent, background It describes treatment regimens, including dosage adjustments, for patients who are also receiving drugs that induce the CYP3A4 enzyme, which metabolizes maribavir ’170 Patent, summary
• Asserted Claims: The complaint does not specify asserted claims Compl. ¶78
• Accused Features: The complaint alleges that the Qilu ANDA Product will infringe, presumably through inducement when its label instructs users to follow the patented dosing regimens Compl. ¶¶80-81

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Qilu's ANDA Product," which is a proposed generic version of LIVTENCITY® comprising 200 mg maribavir tablets, for which Defendant submitted ANDA No. 221142 to the FDA Compl. ¶27 Compl. ¶31

Functionality and Market Context

The Qilu ANDA Product is an antiviral drug intended for the treatment of post-transplant cytomegalovirus (CMV) infection/disease in adult and pediatric patients Compl. ¶10 Compl. ¶31 The complaint alleges that upon FDA approval, Defendant will manufacture, use, import, offer for sale, and sell this generic product throughout the United States Compl. ¶28 The act of infringement giving rise to the suit under the Hatch-Waxman Act is the submission of the ANDA itself Compl. ¶27 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or sufficient detail to construct one with precision. The infringement allegations are based on the premise that Defendant's proposed generic product will be used in a manner that infringes Plaintiff's method claims, and that the product itself may infringe composition or process claims. The narrative theory for the method claims is that the label for the Qilu ANDA Product will instruct and encourage physicians and patients to administer the drug in a manner that directly infringes the patented methods Compl. ¶13

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of key claim terms.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all six patents-in-suit. Inducement is premised on the allegation that the FDA-approved labeling for LIVTENCITY® instructs users to administer the drug according to the patented methods and that Defendant's generic label will do the same Compl. ¶13 Compl. ¶36 Contributory infringement is alleged on the basis that the Qilu ANDA Product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶37
• Willful Infringement: The complaint does not contain a formal count for willful infringement but alleges for each patent that the case is "an exceptional one" and that Plaintiff is entitled to attorneys' fees under 35 U.S.C. § 285 Compl. ¶40 Compl. ¶49 Compl. ¶58 Compl. ¶67 Compl. ¶76 Compl. ¶85 The basis for this allegation is Defendant's alleged knowledge of the patents-in-suit since at least the date of its ANDA submission Compl. ¶38 Compl. ¶47 Compl. ¶56 Compl. ¶65 Compl. ¶74 Compl. ¶83

VII. Analyst’s Conclusion: Key Questions for the Case

1. A central issue will be one of induced infringement: Will the final, FDA-approved label for Qilu’s generic maribavir product contain instructions or recommendations that encourage physicians and patients to administer the drug in a manner that directly practices the specific dosing regimens and conditions of use recited in the asserted method claims?
2. A key evidentiary question will arise for the composition and synthesis patent ('940 Patent): Can Takeda demonstrate, through discovery and analysis, that Qilu's ANDA product either possesses the specific impurity profile claimed in the patent or is manufactured using a process that falls within the scope of the patent’s method claims?
3. The case may also turn on questions of claim construction and validity: How will the court construe terms such as "fasted condition" from the '632 and '169 patents, and will the asserted claims of all six patents withstand potential validity challenges from the Defendant based on prior art or other statutory requirements?